EUVIMEDEUVIMED entdecken
Multizentrische Studie

Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy

Reuben Ben-David iD, Francesco Pellegrino iD, Reza Mehrazin iD, Joel Thomas iD, Jack Geduldig iD, Sarah Lidagoster iD, Evan B Garden iD, Kyrollis Attalla iD, Ahmed Eraky iD, Paolo Zaurito iD, Marco Moschini iD, Alberto Briganti iD und 3 weitere

BJU International · 2025

DOI: 10.1111/bju.16662 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, 2025. Verfasst von Reuben Ben-David und 14 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. Hauptthemen laut MEDLINE: Cystectomy, Neoadjuvant Therapy, Urinary Bladder Neoplasms, Postoperative Complications. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess 30‐ and 90‐day postoperative complication rates in patients who underwent robot‐assisted radical cystectomy (RARC) after receiving novel immunotherapy‐based neoadjuvant treatment.

Methods

A bi‐centre analysis was conducted in patients who underwent RARC with intracorporeal urinary diversion and who received an immunotherapy‐based neoadjuvant regimen between 2017 and 2023. Complications were classified using the Clavien–Dindo system.

Results

The cohort included 136 patients, with a median (interquartile range [IQR]) age of 66 (61–73) years, of whom 22 were female (16.2%). The overall 30‐day and 31–90‐day Clavien–Dindo grade ≥3a complication rates were 15.4%, and 14.7%, respectively. The most common cumulative 90‐day complications by category were infectious (59.6%), genitourinary (33.1%), and gastrointestinal (22.7%). The median (IQR) hospital stay was 11 (7–16) days, and 36 patients (26.5%) required readmission. Eighty‐four patients received monotherapy with an immune checkpoint inhibitor and 52 received combination immunochemotherapy. A higher rate of 30‐day infectious complications was seen in the immuno‐monotherapy group (46.4% vs 26.9%; P = 0.03), while pulmonary complications were more commonly reported in the combination immunochemotherapy group (9.6% vs 1.2%; P = 0.03). No statistically significant differences were found in the other complication categories between the groups. Eleven patients (8.1%) experienced 13 (9.6%) immune‐related adverse events (irAEs). The most common irAEs were hypothyroidism and dermatitis.

Conclusions

The cumulative 90‐day complication rate after novel immunotherapy‐based neoadjuvant treatment appears higher than those previously reported for RARC alone or for chemotherapy‐based neoadjuvant regimens. We observed irAEs in 8.1% of patients after RARC, highlighting the need for urologists to recognise such events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CystectomyNeoadjuvant TherapyUrinary Bladder NeoplasmsPostoperative ComplicationsImmunotherapyImmune Checkpoint InhibitorsHumansFemaleMaleAgedMiddle AgedRetrospective StudiesRobotic Surgical Procedures

Stichwörter der Autor:innen

immunotherapyneoadjuvant therapyperi‐operative complicationsradical cystectomyrobot‐assisted radical cystectomyurinary diversion

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Urology Department, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
  • Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.

ORCID-Profile: Reuben Ben-David, Francesco Pellegrino, Reza Mehrazin, Joel Thomas, Jack Geduldig, Sarah Lidagoster, Evan B Garden, Kyrollis Attalla, Ahmed Eraky, Paolo Zaurito, Marco Moschini, Alberto Briganti, Francesco Montorsi, John P Sfakianos, Peter Wiklund

Zitieren

APA

Ben-David, R., Pellegrino, F., Mehrazin, R., Thomas, J., Geduldig, J., Lidagoster, S., Garden, E. B., Attalla, K., Eraky, A., Zaurito, P., Moschini, M., Briganti, A., Montorsi, F., Sfakianos, J. P., & Wiklund, P. (2025). Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy. BJU International. https://doi.org/10.1111/bju.16662

Vancouver

Ben-David R, Pellegrino F, Mehrazin R, Thomas J, Geduldig J, Lidagoster S, et al. Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy. BJU International. 2025. doi:10.1111/bju.16662

BibTeX
@article{BenDavid2025,
  author = {Ben-David, Reuben and Pellegrino, Francesco and Mehrazin, Reza and Thomas, Joel and Geduldig, Jack and Lidagoster, Sarah and Garden, Evan B and Attalla, Kyrollis and Eraky, Ahmed and Zaurito, Paolo and Moschini, Marco and Briganti, Alberto and Montorsi, Francesco and Sfakianos, John P and Wiklund, Peter},
  title = {Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16662}
}
Kostenlos starten →